Chemokine CC-ligand 5 production and eosinophil activation into the upper airways of aspirin-sensitive patients

Clinical and Experimental Allergy

Volumn 39, Issue 4, 2009, Pages 491-499

  Fuentes Beltran A ^a   Montes Vizuet, R ^a   Valencia Maqueda, E ^a   Negrete Garcia M C ^a   García Cruz, M De L ^a   Teran, L M ^a  

^a INSTITUTO NACIONAL DE ENFERMEDADES RESPIRATORIAS   (Mexico)

Author keywords

Aspirin sensitivity; CCL5 RANTES; ECP; Eosinophils; Leukotrienes

Indexed keywords

ACETYLSALICYLIC ACID; EOSINOPHIL CATIONIC PROTEIN; LEUKOTRIENE DERIVATIVE; LYSINE ACETYLSALICYLATE; RANTES; SODIUM CHLORIDE;

ADULT; ARTICLE; ASTHMA; CELL ACTIVATION; CONCENTRATION (PARAMETERS); CONTROL GROUP; CONTROLLED STUDY; CYTOKINE PRODUCTION; EOSINOPHIL; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; NOSE MUCUS; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROVOCATION TEST; RESPIRATORY EPITHELIUM; RHINOSINUSITIS; TISSUE CULTURE; UPPER RESPIRATORY TRACT;

ADMINISTRATION, INTRANASAL; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; ASTHMA; CHEMOKINE CCL5; DRUG HYPERSENSITIVITY; EOSINOPHIL CATIONIC PROTEIN; EOSINOPHILS; HUMANS; LEUKOTRIENES; MIDDLE AGED; NASAL LAVAGE FLUID; RHINITIS, ALLERGIC, PERENNIAL; SINUSITIS;

EID: 62449093632     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/j.1365-2222.2008.03190.x     Document Type: Article

References (35)

1. Stevenson DD, Szczeklik A. Clinical and pathologic perspectives on aspirin sensitivity and asthma. J Allergy Clin Immunol 2006 118 : 773 86.
2. Peréz-Novo CA, Watelet JB, Claeys C, Van Cauwenberge P, Bachert C. Prostaglandin, leukotriene, and lipoxin balance in chronic rhinosinusitis withand without nasal polyposis. J Allergy Clin Immunol 2005 115 : 1189 96.
3. Kowalski ML, Pawliczak R, Wozniak J et al. Differential metabolism of arachidonic acid in nasal polyp epithelial cells cultured from aspirin-sensitive and aspirin-tolerant patients. Am J Respir Crit Care Med 2000 161 : 391 8.
4. Pierzchalska M, Zsabó Z, Sanak M, Soja J, Szczeklik A. Deficient prostaglandin E2 production by bronchial fibroblasts of asthmatic patients, with special reference to aspirin-induced asthma. J Allergy Clin Immunol 2003 111 : 1041 8.
5. Ferreri NR, Howland WC, Stevenson DD, Spiegelberg HL. Release of leukotrienes, prostaglandins, and histamine into nasal secretions of aspirin-sensitive asthmatics during reaction to aspirin. Am Rev Respir Dis 1988 137 : 847 54.
6. Cowburn AS, Sladek K, Soja J et al. Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma. J Clin Invest 1998 101 : 834 46.
7. Dahlen SE, Malmstrom K, Nizankowska E et al. Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: a randomized, double-blind, placebo-controlled trial. Am J Respir Crit Care Med 2002 165 : 9 14.
8. Micheletto C, Tognella S, Visconti M, Pomari C, Trevisan F, Dal Negro RW. Montelukast 10 mg improves function and nasal function and nasal response to aspirin in ASA-sensitive asthmatics: controlled study vs placebo. Allergy 2005 60 : 289 94.
9. Sestini P, Armetti L, Gambaro G et al. Inhaled PGE2 prevents aspirin-induced bronchoconstriction and urinary LTE4 excretion in aspirin-sensitive asthma. Am J Respir Crit Care Med 1996 153 : 572 5.
10. Szczeklik A, Mastalerz L, Nizankowska E, Cmiel A. Protective and bronchodilator effects of prostaglandin E and salbutamol in aspirin induced asthma. Am J Respir Crit Care Med 1996 153 : 567 71.
11. Kay AB. The role of eosinophils in the pathogenesis of asthma. Trends Mol Med 2005 11 : 148 52.
12. Rothemberg ME, Hogan SP. The eosinophil. Ann Rev Immunol 2006 24 : 147 74 Review.
13. Adamjee J, Suh YJ, Park HS et al. Expression of 5-lipoxygenase and cyclooxygenase pathway enzymes in nasal polyps of patients with aspirin-intolerant asthma. J Pathol 2006 209 : 392 9.
14. Teran LM. CCL chemokines and asthma. Immunol Today 2000 21 : 235 42.
15. Dairaghi DJ, Soo KS, Oldham ER et al. RANTES induced T cell activation correlates with CD3 expression. J Immunol 1998 160 : 426 33.
16. Holgate ST, Bodey KS, Janezic A, Frew AJ, Kaplan AP, Teran LM. Release of RANTES, MIP-1 alpha, and MCP-1 into asthmatic airways following endobronchial allergen challenge. Am J Respir Crit Care Med 1997 156 : 1377 83.
17. Pods R, Ross D, van Hulst S, Rudack C, Maune S. RANTES, eotaxin and eotaxin-2 expression and production in patients with aspirin triad. Allergy 2003 58 : 1165 70.
18. Casadevall J, Ventura PJ, Mullol J, Picado C. Intranasal challenge with aspirin in the diagnosis of aspirin intolerant asthma: evaluation of nasal response by acoustic rhinometry. Thorax 2000 55 : 921 4.
19. Rojas-Ramos E, Garfias-Becerra Y, Jimenez-Martinez MC et al. Cell surface markers in patients with allergic rhinitis versus Der p and Der f challenge. Rev Alerg Mex 2000 47 : 190 6.
20. Kowalski ML, Grzegorczyk J, Wojciechowska B, Poniatowska M. Intranasal challenge with aspirin induces cell influx and activation of eosinophils and mast cells in nasal secretions of ASA-sensitive patients. Clin Exp Allergy 1996 26 : 807 14.
21. Lezcano-Meza D, Davila-Davila B, Vega-Miranda A, Negrete-Garcia MC, Teran LM. Interleukin (IL)-4 and to a lesser extent either IL-13 or interferon-gamma regulate the production of eotaxin-2/CCL24 in nasal polyps. Allergy 2003 58 : 1011 7.
22. Montes-Vizuet R, Vega-Miranda A, Valencia-Maqueda E, Negrete-Garcia MC, Velasquez JR, Teran LM. CC chemokine ligand 1 is released into the airways of atopic asthmatics. Eur Respir J 2006 28 : 59 67.
23. Sousa AR, Lams BE, Pfister R, Christie PE, Schmitz M, Lee TH. Expression of interleukin-5 and granulocyte-macrophage colony-stimulating factor in aspirin-sensitive and non-aspirin-sensitive asthmatic airways. Am J Respir Crit Care Med 1997 156 : 1384 9.
24. Negrete-García MC, Fuentes-Beltran A, Valencia-Maqueda E, Garcia-Cruz ML, Teran LM. The chemokines in aspirin-exacerbated respiratory disease. LX National Congr Clin Immunol Allergy (CMICA) 2006 60 : A17.
25. Teran LM, Noso N, Carroll M, Davies DE, Holgate S, Schroder JM. Eosinophil recruitment following allergen challenge is associated with the release of the chemokine RANTES into asthmatic airways. J Immunol 1996 157 : 1806 12.
26. Spada CS, Nieves AL, Krauss AH, Woodward DF. Comparison of leukotriene B4 and D4 effects on human eosinophils and neutrophil mobility in vitro. J Leuk Biol 1994 55 : 183 9.
27. +progenitors. Immunology 2000 101 : 419 25.
28. Oyamada H, Kamada Y, Saito N et al. RANTES production from mononuclear cells in response to the specific allergen in asthma patients. Allergol Int 2006 55 : 253 9.
29. Teran LM, Mochizuki M, Bartels J et al. Th1- and Th2-type cytokines regulate the expression and production of eotaxin and RANTES by human lung fibroblasts. Am J Respir Cell Mol Biol 1999 20 : 777 86.
30. Kanda A, Adachi T, Kayaba H et al. Red blood cells regulate eosinophil chemotaxis by scavenging RANTES secreted from endothelial cells. Clin Exp Allergy 2004 34 : 1621 6.
31. Teran LM, Park HS, Djukanovic R, Roberts K, Holgate S. Cultured nasal polyps from nonatopic and atopic patients release RANTES spontaneously and after stimulation with phytohemagglutinin. J Allergy Clin Immunol 1997 100 : 499 504.
32. Miyabayashi K, Maruyama M, Yamada T et al. Isoproterenol suppresses cytokine-induced RANTES secretion in human lung epithelial cells through the inhibition of c-jun N-terminal kinase pathway. Biochem Biophys Res Commun 2006 350 : 753 61.
33. Beck LA, Stellato C, Beall LD et al. Detection of the chemokine RANTES and endothelial adhesion molecules in nasal polyps. J Allergy Immunol 1996 98 : 766 80.
34. Wang JH, Devalia JL, Xia C, Sapsford RJ, Davies RJ. Expression of RANTES by human bronchial epithelial cells in vitro and in vivo and the effect of corticosteroids. Am J Respir Cell Mol Biol 1996 14 : 27 35.
35. Kameyoshi Y, Dörschner A, Mallet AI, Christophers E, Schröder J. Cytokine RANTES released by thrombin-stimulated platelets is a potent attractant for human eosinophils. J Exp Med 1992 176 : 587 92.